Combines DVS Sciences' High-Parameter Single-Cell Protein Analysis Platform with...

Fluidigm Announces Preliminary Fourth Quarter 2013 Revenue and Issues 2014 Revenue Guidance   SOUTH SAN FRANCISCO, Calif. – Jan. 14, 2014 – Fluidigm Corporation (NASDAQ:FLDM) today announced total revenue for the fourth quarter of 2013 is expected to be approximately $21 million based on

Fluidigm to Present at the 32nd Annual J.P. Morgan Healthcare Conference    SOUTH SAN FRANCISCO, Calif. – Jan. 8, 2014 – Fluidigm Corporation (NASDAQ:FLDM) today announced that President and Chief Executive Officer Gajus Worthington will present at the 32nd Annual J.P.

Nature Selects "Single-Cell Sequencing" as the 2013 Method of the Year
Fluidigm Technology Accelerates the Adoption and Impact of Single-Cell Sequencing

Fluidigm Launches Single-Cell DNA Sequencing Workflow to Study Somatic Mutations in Heterogenous Samples
Universal Sample Prep Workflow on C1&#8482 Single-Cell Auto Prep System Simplifies Genome-Wide and Targeted Sequencing

For Immediate Release

Fluidigm to Present at the Credit Suisse 2013 Healthcare Conference

Strong Q3 2013 revenue growth of 43%

Fluidigm to Announce Q3 2013 Financial Results and Host Conference Call for Investors

Fluidigm and Nanostring Agree to Litigation Settlement
NanoString to Refrain From Using Single-Cell Comparison Study Marketing Materials